Evidence map›Paper›PMID 25987625›Full record

ArticleAntimicrobial agents and chemotherapy2015

Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy.

Stephan Karl, Moses Laman, Brioni R Moore, John Benjamin, Tamarah Koleala, Clemencia Ibam, Bernadine Kasian, Peter M Siba, Andreea Waltmann, Ivo Mueller and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. The American journal of tropical medicine and hygiene · 2019
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Stephan KarlSchool of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia Infection and Immunity Division, Walter and Eliza Hall Institute, Parkville, Victoria, Australia Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Moses LamanSchool of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Brioni R MooreSchool of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
John BenjaminPapua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Tamarah KolealaPapua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Clemencia IbamPapua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Bernadine KasianPapua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Peter M SibaPapua New Guinea Institute of Medical Research, Madang, Papua New Guinea Department of Microbiology, Division of Veterinary and Biomedical Sciences, James Cook University, Townsville, Australia.
Andreea WaltmannInfection and Immunity Division, Walter and Eliza Hall Institute, Parkville, Victoria, Australia Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Ivo MuellerInfection and Immunity Division, Walter and Eliza Hall Institute, Parkville, Victoria, Australia Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia Centre de Recerca en Salut Internacional de Barcelona (CRESIB), Barcelona, Spain.
Robert C WoodwardSchool of Physics, University of Western Australia, Crawley, Western Australia.
Timothy G St PierreSchool of Physics, University of Western Australia, Crawley, Western Australia.
Timothy M E DavisSchool of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia tim.davis@uwa.edu.au.
Papua New Guinea Institute of Medical Research · PGUniversity of Western Australia · AUFremantle Hospital · AUWalter and Eliza Hall Institute of Medical Research · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantitative magnetic fractionation and a published mathematical model were used to characterize between-treatment differences in gametocyte density and prevalence in 70 Papua New Guinean children with uncomplicated Plasmodium falciparum and/or Plasmodium vivax malaria randomized to one of two artemisinin combination therapies (artemether-lumefantrine or artemisinin-naphthoquine) in an intervention trial. There was an initial rise in peripheral P. falciparum gametocyte density with both treatments, but it was more pronounced in the artemisinin-naphthoquine group. Model-derived estimates of the median pretreatment sequestered gametocyte population were 21/μl for artemether-lumefantrine and 61/μl for artemisinin-naphthoquine (P < 0.001). The median time for P. falciparum gametocyte density to fall to <2.5/μl (below which transmission becomes unlikely) was 16 days in the artemether-lumefantrine group and 20 days in artemisinin-naphthoquine group (P < 0.001). Gametocyte prevalence modeling suggested that artemisinin-naphthoquine-treated children became gametocytemic faster (median, 2.2 days) than artemether-lumefantrine-treated children (median, 5.3 days; P < 0.001) and had a longer median P. falciparum gametocyte carriage time per individual (20 versus 13 days; P < 0.001). Clearance of P. vivax gametocytes was rapid (within 3 days) in both groups; however, consistent with the reappearance of asexual forms in the main trial, nearly 40% of children in the artemether-lumefantrine group developed P. vivax gametocytemia between days 28 and 42 compared with 3% of children in the artemisinin-naphthoquine group. These data suggest that artemisinin is less active than artemether against sequestered gametocytes. Greater initial gametocyte release after artemisinin-naphthoquine increases the period of potential P. falciparum transmission by 4 days relative to artemether-lumefantrine, but the longer elimination half-life of naphthoquine than of lumefantrine suppresses P. vivax recurrence and consequent gametocytemia.

Indexed as

AntimalarialsArtemetherArtemisininsChild, PreschoolDrug Therapy, CombinationEthanolaminesFemaleFluorenesHalf-LifeHumansKineticsLumefantrineMalaria, FalciparumMalaria, VivaxMaleNaphthoquinonesAntimalarialsArtemetherartemisininArtemisininsEthanolaminesFluorenesLumefantrineNaphthoquinones

Identifiers

PMID25987625
PMCPMC4505274
OpenAlexW1900916077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.